CONTRIBUTOR
Contributor Image
glenn_doody

Glenn Doody

Vice President, Product Management, Technology Innovation and Specialty Products, S&P Dow Jones Indices

Glenn Doody is Vice President, Product Management, Technology Innovation and Specialty Products at S&P Dow Jones Indices (S&P DJI). Glenn’s responsibilities include the oversight of development of innovative new technologies for S&P DJI products. In addition, Glenn is responsible for the S&P CoreLogic Case-Shiller Home Price Indices and S&P/Experian Consumer Credit Indices. In Glenn’s previous role as Chief Operating Officer of Trucost, he focused on improving growth opportunities, introducing processes aimed at increasing revenue generation and profitability, as well as technology development.
Full Bio
Apr 10, 2017

Alaska Healthcare Profiled

According to an April 6, 2017, CNN story titled “High-cost Alaska sits in the eye of health care reform storm,” Alaska currently has the highest healthcare costs of any U.S. state.[1]  In this first profile edition, we look at the state of Alaska and compare just how different the cost profile is for people living…

READ

Dec 22, 2016

Employer Self-Insured Trends Still Moving Upward

According to the S&P Healthcare Claims Indices, employers should be cautious about getting comfortable with trends in the 4.5%-5% range.  While the most recent data indicates that trends dropped from almost 5% in June 2016 to around 4.5% in July 2016, the overall movement of the trend is still upward.  The S&P National Medical Healthcare…

READ

Nov 4, 2016

Latest Healthcare Cost Analysis Shows Individual Market Trends in Line With Employer Trends! – Part 2

In our last post, we talked about how individual line of business costs have come back in line with employer healthcare costs (see Exhibit 1).  In that piece, we discussed that one possible reason for this could be that individuals buying insurance for the first time under the new provisions of the Affordable Care Act…

READ

Oct 27, 2016

Latest Healthcare Cost Analysis Shows Individual Market Trends in Line With Employer Trends! – Part 1

There are many in the healthcare market who have speculated that the Affordable Care Act (ACA) was doomed to fail due to high-cost individuals with pre-existing conditions driving up the average cost of care, while the healthy population that needed to support the cost of care for the sick remained on the sidelines with little-to-no…

READ

Apr 28, 2016

Are employers’ efforts to control healthcare costs futile?

The question for the future of the private insurance system is this: are employers’ efforts to control healthcare costs futile?  Recent data from the S&P Healthcare Claims Indices would suggest that this may actually be the case.  According to the indices, costs for self-insured employers, known as Administrative Services Only (ASO) in the healthcare industry,…

READ

Mar 31, 2016

Has the ACA Achieved its Goal of Significantly Increasing Enrollment While Making Healthcare Coverage More Affordable? Part 2

In part 2 of this blog series, we will look at the effect the 25%+ increase in new membership related to the Affordable Health Care Act (ACA) has had on costs.  From the time of the initial drafting of the ACA rules, there was concern that the new enrollees in the individual insurance market would…

READ

Mar 24, 2016

Has the Affordable Care Act Achieved its Goal of Significantly Increasing Enrollment While Making Healthcare Coverage More Affordable? Part 1

The Affordable Care Act (ACA), signed on March 23, 2010, by President Barack Obama, has often been described as legislation to 1) make healthcare and health insurance more affordable, and 2) make health insurance more broadly available to Americans.  Key parts of the ACA have been discussed relentlessly in the market, in particular the requirements…

READ

Oct 20, 2015

The Effects of Regulation on Prescription Drugs

According to a story in Canada’s Globe and Mail, one drug maker is about to take on an entire country to protect its right to price drugs the way they see fit.  Alexion Pharmaceuticals, the maker of the drug Soliris, has announced a lawsuit against Canada’s Patented Medicine Prices Review Board after the board began…

READ

Sep 20, 2015

Daraprim Price Increase–The Effect on Generic Drug Costs

The week of Sept. 21, 2015, saw a flurry of stories about the escalating cost of drugs in the U.S. marketplace. These stories were all initiated by Turing Pharmaceuticals buyout of the drug Daraprim (NY Times Story) and the decision to increase the price per tablet from USD 13.50 to USD 750.00. Turing’s stated reason…

READ

May 29, 2015

The Effects of the Affordable Care Act on the S&P Healthcare Claims National Index

On May 21, 2015 an article appeared in the Wall Street Journal stating that health insurance providers are seeking hefty rate increases for individual health plans in 2016.  Industry analysts had already expected the cost for individual polices to increase because of two changes made by the Affordable Care Act. The elimination of medical underwriting,…

READ


Sign up to receive Indexology® Blog email updates